The 0.01 mg/kg dose that showed consistent effects in rats translates to approximately 0.0016 to 0.004 mg/kg in humans, which works out to roughly 0.112 to 0.28 mg for a 154-pound person
Oral BPC-157 works directly on the GI mucosa, while injectable BPC-157 and Thymosin Alpha-1 offer systemic and immune-focused support
It is essential to note that recovery times are influenced by the severity of the injury and the area being treated
For Research Use Only Not for Human or Veterinary Consumption
3 In normoxia, HIF1A protein is targeted for degradation by cytosolic prolyl hydroxylases, while in hypoxia, these prolyl hydroxylases are inhibited, allowing HIF1A to translocate to the nucleus, dimerize with HIF1 protein, and the dimer then binds to hypoxia response elements to modulate transcription of target genes, prompting changes in metabolism and angiogenesis to promote survival